Abstract
Ever since pure molecular entities have been adapted as drug, varied manifestations other than elimination of infections are frequently been acknowledged as side effects. Contemporary drug research focuses on these issues besides developing new molecules for the restoration of unnatural functional deviations in various tissues and organs. The most promising advancement to achieve this concept of ideal drug is the encapsulation of drug in biocompatible nano or microspheres. Encapsulation can insulate the toxic drugs and lease a better half life to molecules undergoing spontaneous degradation under physiological conditions. It is also worthwhile to incorporate along some immunomodulators to strengthen and channelize the innate immune response of the host in right direction. This holistic approach would also prevent the physiological modulations dictated by invading pathogens, which paralyze the important functionaries of the host. Lipoproteins, lipid like molecules and probiotic non-colonizing bacterial membrane mimics might prove to be the best ingredients for encapsulation. Some synthetic non-immunogenic supra molecules like fullarenes and dendrimers also exhibit great potential for the development of new encapsulation technology. Here an attempt is made to review the progress in terms of aims and achievements in the area of drug carriers and encapsulation with its overall impact on therapeutic industry.
Keywords: Drug carriers, liposomes, fullerenes, dendrimers, drug-conjugates
Current Pharmaceutical Design
Title: Drug Carriers in Pharmaceutical Design: Promises and Progress
Volume: 13 Issue: 7
Author(s): Ranjna C. Dutta
Affiliation:
Keywords: Drug carriers, liposomes, fullerenes, dendrimers, drug-conjugates
Abstract: Ever since pure molecular entities have been adapted as drug, varied manifestations other than elimination of infections are frequently been acknowledged as side effects. Contemporary drug research focuses on these issues besides developing new molecules for the restoration of unnatural functional deviations in various tissues and organs. The most promising advancement to achieve this concept of ideal drug is the encapsulation of drug in biocompatible nano or microspheres. Encapsulation can insulate the toxic drugs and lease a better half life to molecules undergoing spontaneous degradation under physiological conditions. It is also worthwhile to incorporate along some immunomodulators to strengthen and channelize the innate immune response of the host in right direction. This holistic approach would also prevent the physiological modulations dictated by invading pathogens, which paralyze the important functionaries of the host. Lipoproteins, lipid like molecules and probiotic non-colonizing bacterial membrane mimics might prove to be the best ingredients for encapsulation. Some synthetic non-immunogenic supra molecules like fullarenes and dendrimers also exhibit great potential for the development of new encapsulation technology. Here an attempt is made to review the progress in terms of aims and achievements in the area of drug carriers and encapsulation with its overall impact on therapeutic industry.
Export Options
About this article
Cite this article as:
Dutta C. Ranjna, Drug Carriers in Pharmaceutical Design: Promises and Progress, Current Pharmaceutical Design 2007; 13 (7) . https://dx.doi.org/10.2174/138161207780249119
DOI https://dx.doi.org/10.2174/138161207780249119 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: New Therapeutic Targets in Clinical Medicine)
Current Pharmaceutical Design Efalizumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging Blood Pressure Measurement: Lessons Learned from Our Ancestors
Current Pharmaceutical Design Biological Consequences of Dysfunctional HDL
Current Medicinal Chemistry The Role of COX-2 in Heart Pathology
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Potential of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors for the Treatment of Retinal and Eye Diseases
CNS & Neurological Disorders - Drug Targets Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Emerging Therapies for Type 2 Diabetes
Current Drug Therapy Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology Metabolic Syndrome During Menopause
Current Vascular Pharmacology Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Heart Disease Prediction System Using Decision Tree and Naive Bayes Algorithm
Current Medical Imaging Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide
Current Pharmaceutical Biotechnology In Vitro Antioxidant Activity of Selected Medicinal Plants Reported in Ancient Ayurveda Traditions
Current Traditional Medicine Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA Nutritional Antioxidants and Their Applications in Cardiometabolic Diseases
Infectious Disorders - Drug Targets Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry HDL-C Levels and Cardiovascular Disease: More is not Always Better!
Recent Patents on Cardiovascular Drug Discovery Acute Respiratory Failure in Obstetric Patients
Current Women`s Health Reviews